In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-a

REFERENCES

• Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). hit J Exp Pathol 2001;82: 135–147.
   Google Scholar
• Mesnard JM, Devaux C. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology 1999;257:277–284.
   Google Scholar
• Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR. Abundant tax protein expression in CD4 + T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000;95:1386–1392.
   Google Scholar
• Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003;115:449–459.
   Google Scholar
• Inoue J, Itoh M, Akizawa T, Toyoshima H, Yoshida M. HTLV-1 Rex protein accumulates unspliced RNA in the nucleus as well as in cytoplasm. Oncogene 1991;6: 1753–1757.
   Google Scholar
• Meertens L, Chevalier S, Weil R, Gessain A, Mahieux R. A 10-Amino Acid Domain within Human T-cell Leukemia Virus Type 1 and Type 2 Tax Protein Sequences Is Responsible for Their Divergent Subcellular Distribution. J Biol Chem 2004;279: 43307–43320.
   Google Scholar
• Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004;279:31991–31994.
   Google Scholar
• Grassmann R, Fleckenstein B, Desrosiers RC. Viral trans-formation of human T lymphocytes. Adv Cancer Res 1994;63:211–244.
   Google Scholar
• Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol 1990;10:413–417.
   Google Scholar
• Liang MH, Geisbert T, Yao Y, Hinrichs SH, Giam CZ. Human T-lymphotropic virus type 1 oncoprotein tax promotes S-phase entry but blocks mitosis. J Virol 2002;76: 4022–4033.
   Google Scholar
• Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1995;92:1057–1061.
   Google Scholar
• Yin MJ, Gaynor RB. Complex formation between CREB and Tax enhances the binding affinity of CREB for the human T-cell leukemia virus type 1 21-base-pair repeats. Mol Cell Biol 1996;16:3156–3168.
   Google Scholar
• Jiang H, Lu H, Schiltz RL, Pise-Masison CA, Ogryzko VV, Nakatani Y, Brady JN. PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner. Mol Cell Biol 1999;19:8136–8145.
   Google Scholar
• Harrod R, Tang Y, Nicot C, Lu HS, Vassilev A, Nakatani Y, Giam CZ. An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol 1999;18: 5052–5061.
   Google Scholar
• Koga H, Ohshima T, Shimotohno K. Enhanced activation of tax dependent transcription of HTLV-I LTR by TORC3. J Biol Chem. 2004; in press.
   Google Scholar
• Sun SC, Harhaj EW, Xiao G, Good L. Activation of I-kappaB kinase by the HTLV type 1 Tax protein: mechanistic insights into the adaptor function of IKKgamma. AIDS Res Hum Retroviruses 2000;16:1591–1596.
   Google Scholar
• Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C, Brady JN. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax (In Process Citation). AIDS Res Hum Retroviruses 2000;16: 1669–1675.
   Google Scholar
• Yoshida M, Suzuki T. HTLV type 1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity (In Process Citation). AIDS Res Hum Retroviruses 200016:1639-1645.
   Google Scholar
• Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J, Zermati Y, Mauviel A, Bazarbachi A, Hermine 0. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002;100: 4129–4138.
   Google Scholar
• Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003;22:5131–5140.
   Google Scholar
• Gatza ML, Watt JC, Marriott SJ. Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades. Oncogene 2003;22:5141–5149.
   Google Scholar
• Jeang KT, Widen SG, Semmes OJT, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990;247:1082–1084.
   Google Scholar
• Suzuki T, Uchida-Toita M, Andoh T, Yoshida M. HTLV-1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity. Virology 2000;270:291–298.
   Google Scholar
• Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot J, Brown M, Kazanji M, Barrett J, Nicot C. Transcriptional activation of hTERT in HTLV-1 trans-formed cells through the NF-kB pathway. Blood 2004;104: 2523–2531.
   Google Scholar
• Gabet AS, Mortreux F, Charneau P, Riou P, Duc-Dodon M, Wu Y, Jeang KT, Wattel E. Inactivation of hTERT transcription by Tax. Oncogene 2003;22:3734–3741.
   Google Scholar
• Yamaguchi K, Nishimura H, Kohrogi H, Jono M, Miyamoto Y, Takatsuki K. A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood 1983;62:758–766.
   Google Scholar
• Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002;76 Suppl 2:S240–S245.
   Google Scholar
• Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Mono-clonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984;81:2534–2537.
   Google Scholar
• Asquith B, Hanon E, Taylor GP, Bangham CR. Is human T-cell lymphotropic virus type I really silent? Philos Trans R Soc Lond B Biol Sci 2000;355:1013–1019.
   Google Scholar
• Arnulf B, Thorel M, Poirot Y, Tamouza R, Boulanger E, Jaccard A, Oksenhendler E, Hermine 0, Pique C. Loss of the ex vivo but not the reinducible CD8 + T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004;18: 126–132.
   Google Scholar
• Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571–573.
   Google Scholar
• Fouchard N, Flageul B, Bagot M, Avril MF, Hermine 0, Sigaux F, Merle-Beral H, Troussard X, Delfraissy JF, de The G, et al. Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases. Leukemia 1995;9: 2087–2092.
   Google Scholar
• Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood 1984;63:1235–1240.
   Google Scholar
• Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 1990;45:237–243.
   Google Scholar
• Anonymous. The third nation-wide study on adult T-cell leukemia/lymphoma (ATL) in Japan: characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. The T- and B-cell Malignancy Study Group. hit J Cancer 1988;41:505–512.
   Google Scholar
• Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I, Koba T, Takahashi T, Saito H, Doi H, Shirahama S. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. hit J Cancer 2000;85:319–324.
   Google Scholar
• Hermine 0, Wattel E, Gessain A, Bazarbachi A. Adult T Cell Leukemia, a review of established and new treatments. BioDrugs 1998;10:447–462.
   Google Scholar
• Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood 1989;73:1664–1671.
   Google Scholar
• Takatsuki K, Yamaguchi K, Matsuoka M. Adult T-cell leukemia. In: Holsberg HDP, editor. Human T Cell Lymphotropic Virus Type 1. New York: Wiley; 1996. pp 219–246.
   Google Scholar
• Uchiyama T, Ishikawa T, Kondo A. hi: Takatsuki T, editor. Adult T-cell Leukemia. Pathophysiology of ATL cells: cell growth characteristics Oxford: Oxford University Press; 1994. pp 181–203.
   Google Scholar
• Hermine 0, Arnulf B, Bazarbachi A. Treatment of adult-T cell leukemia/lymphoma: clinical results of new therapeutic approaches. AIDS Res Hum retroviruses 2001;17: 529.
   Google Scholar
• Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia/lymphoma. Curr Treat Options Oncol 2001;2:291–300.
   Google Scholar
• Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsuno-miya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113: 375–382.
   Google Scholar
• Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The ME, El Sabbon ME, Hermine 0. Novel therapeutic approaches for adult T cell leukemia. Lancet Oncol 2004;5:664–672.
   Google Scholar
• Zhang J, Balestrieri E, Grelli S, Matteucci C, Pagnini V, D'Agostini C, Mastino A, Macchi B. Efficacy of 3'-azido 3'deoxythymidine (AZT) in preventing HTLV-1 transmis-sion to human cord blood mononuclear cells. Virus Res 2001;78: 67–78.
   Google Scholar
• Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, CabralL, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744–1748.
   Google Scholar
• Hermine 0, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, et al. Brief report: treatment of adult T-cell leukemia-lympho-ma with zidovudine and interferon alfa. N Engl J Med 1995;332: 1749–1751.
   Google Scholar
• Bazarbachi A, Hermine 0. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S186–190.
   Google Scholar
• Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001;113:779–784.
   Google Scholar
• Soignet SL, Frankel Sr, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone R1\4, Kalaycio M, Scheinberg DA, Steinherz P, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Chin Oncol 2001;19, 3852–3860.
   Google Scholar
• Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–3360.
   Google Scholar
• Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345–3353.
   Google Scholar
• Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong, SM, et al. hi vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052–1061.
   Google Scholar
• Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705–713.
   Google Scholar
• Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leuke-mia cell lines. Exp Hematol 1999;27:845–852.
   Google Scholar
• Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. hit J Cancer 1999;82:286–292.
   Google Scholar
• Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang 334, Zheng MH. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 1999;4:33–37.
   Google Scholar
• Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP. Arsenic trioxide and melarso-prol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041–1048.
   Google Scholar
• Akay C, Thomas C 3rd, Gazitt Y. Arsenic Trioxide and Paclitaxel Induce Apoptosis by Different Mechanisms. Cell Cycle 2004;3:324–334.
   Google Scholar
• Rojewski MT, Korper S, Thiel E, Schrezenmeier H. Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. Oncol Rep 2004;11:509–513.
   Google Scholar
• Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324–333.
   Google Scholar
• Adachi S, Leoni LM, Carson DA, Nakahata T. Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol 2004;111:107–123.
   Google Scholar
• Ishitsuka K, Hanada S, Suzuki S, Utsunomiya A, Chyuman Y, Takeuchi S, Takeshita T, Shimotakahara S, Uozumi K, Makino T, Arima T. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721–728.
   Google Scholar
• Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, Hermine 0, de The H, Bazarbachi A. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J 2001;2:127–135.
   Google Scholar
• Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, AwarajiC, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine 0, de The H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999;93:278— 283.
   Google Scholar
• Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A Arima T. Arsenic trioxide and the growth of human t-cell leukemia virus type i infected t-cell lines. Leuk Lymphoma 2000;37:649— 655.
   Google Scholar
• El-Sabban ME, Nasr R, Dbaibo G, Hermine 0, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation. Blood 2000;96:2849 — 2855.
   Google Scholar
• Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bc1-2 cleavage. Blood 2001;98:3762— 3769.
   Google Scholar
• Ishitsuka K, Ikeda R, Utsunomiya A, Uozumi K, Hanada S, Suzuki S, Takeuchi S, Takatsuka Y, Takeshita T, Ohno N, Arima T. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma 2002;43: 1107— 1114.
   Google Scholar
• Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine 0, Staudt L, de The H, Bazarbachi A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003;101: 4576— 4582.
   Google Scholar
• Hermine 0, Dombret H, Poupon J, Amulf B, Lefrere F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/ lymphoma. Hematol J 2004;5:130 —134.
   Google Scholar